Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:

NCT ID: NCT03588936 Not yet recruiting - Lymphoma Clinical Trials

Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant

Start date: August 1, 2018
Phase: Phase 1
Study type: Interventional

This is a phase 1, interventional single arm, open label, treatment study designed to evaluate the safety combination PD-1 and IL-6 inhibition in patients with relapsed disease post-allogeneic transplant.

NCT ID: NCT03588598 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia (CLL)

Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignancies

Start date: July 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of SHC014748M in patients with relapsed or refractory indolent B-cell hematologic malignancies.

NCT ID: NCT03586999 Not yet recruiting - Clinical trials for Peripheral T Cell Lymphoma

Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas

Start date: August 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This regimen aims to become the first line treatment for peripheral T cell lymphoma, using nivolumab with the standard of care chemotherapy.

NCT ID: NCT03586024 Recruiting - Lymphoma Clinical Trials

Phase I/II Study of Pembrolizumab in Patients With Relapsed or Refractory Extranodal NK/T- Cell Lymphoma (ENKTL), Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas (EBV-DLBCL)

Start date: July 3, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

To determine the safety and efficacy (overall response rate) of pembrolizumab in patients with relapsed or refractory ENKTL, and EBV-DLBCL

NCT ID: NCT03585725 Recruiting - Clinical trials for Mantle Cell Lymphoma

A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma

Start date: July 2018
Phase: Early Phase 1
Study type: Interventional

This is a A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma

NCT ID: NCT03585465 Not yet recruiting - Clinical trials for Childhood Solid Tumor

Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors or Lymphoma

Start date: September 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The study is a two-stage trial: 1. First stage : Phase I feasibility trial to evaluate the safety of the combination of Nivolumab + metronomic chemotherapy considering three possible metronomic chemotherapy regimens 2. Second stage: Phase II randomized controlled balanced 1:1 open- label trial comparing the efficacy of the metronomic chemotherapy regimen selected at the end of the previous stage, with or without nivolumab.

NCT ID: NCT03583424 Recruiting - Clinical trials for Recurrent Grade 1 Follicular Lymphoma

Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma

Start date: July 9, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effects and best dose of venetoclax when given together with carmustine, etoposide, cytarabine, and melphalan before stem cell transplant in treating participants with non-Hodgkin lymphoma that has come back or does not respond to treatment. Drugs used in chemotherapy, such as venetoclax, carmustine, etoposide, cytarabine, and melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before a stem cell transplant helps kill any cancer cells that are in the body and helps make room in the patient?s bone marrow for new blood-forming cells (stem cells) to grow.

NCT ID: NCT03582254 Recruiting - Clinical trials for Primary Central Nervous System Lymphoma

Role of [18F]-FDG Brain PET in Newly Diagnosed Primary Cerebral Lymphoma, in Immunocompetent Patient Older Than 60 Years

LOCALYSE
Start date: June 13, 2016
Phase: N/A
Study type: Interventional

Patients older than 60 years account for half of cases of Primary Central Nervous System Lymphoma (PCNSL) and have a poorer outcome. No prognostic or predictive factors exist for survival after initial remission. 18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose - Positron Emission Tomography ([18F]FDG-PET) plays a key role in grading and therapy monitoring of systemic diffuse large B-cell type. LOCALYZE is an ancillary Positron Emission Tomography / Magnetic Resonance (PET/MR) clinical study from BLOCAGE 01 (Pr Hoang-Xuan). The aim is to evaluate the usefulness of [18F]FDG-PET to monitor treatment response in PCNSL older than 60 years (n=56), in complement to multiparametric Magnetic Resonance Imaging (MRI). Hypothesis The investigators assume that the development of new imaging biomarker extracted from PET imaging and multiparametric MRI, could improve the assessment of treatment response in PCNSL.

NCT ID: NCT03581942 Not yet recruiting - Clinical trials for Primary Central Nervous System Lymphoma

Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)

Start date: July 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to test the safety of combined use of the study drugs, copanlisib and ibrutinib, in people with PCNSL.

NCT ID: NCT03580564 Not yet recruiting - Clinical trials for Classical Hodgkin Lymphoma

An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma

Start date: July 30, 2018
Phase: Phase 2
Study type: Interventional

The study is to evaluate the efficacy of BGB-A317 a in subjects with relapsed or refractory classical Hodgkin lymphoma (cHL), as measured by Overall Response Rate (ORR) per the Lugano Classification